Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated